Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1909-1919

  Parker, Rex A ^a   Flint, Oliver P ^a   Mulvey, Ruth ^a   Elosua, Carolina ^a   Wang, Faye ^a   Fenderson, William ^a   Wang, Shulin ^a   Yang, Wen Pin ^a   Noor, Mustafa A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; ATAZANAVIR; GLUCOSE; GLUCOSE TRANSPORTER 4; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LOPINAVIR; NELFINAVIR; NUCLEIC ACID BINDING PROTEIN; PROTEASOME; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCOSE TRANSPORTER;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE TRANSPORT; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOGENESIS; LIPOLYSIS; LIVER CELL CULTURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEINASE INHIBITION; STRESS; TRANSCRIPTION INITIATION; UNINDEXED SEQUENCE; ANIMAL; CELL LINE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HYPERLIPIDEMIA; METABOLISM; RAT; WISTAR RAT;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MICE; MONOSACCHARIDE TRANSPORT PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, WISTAR; STRESS;

EID: 21744443279     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.010165     Document Type: Article

References (44)

1. Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, et al. (2004) Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill) 3:92-98.
2. Calza L, Manfredi R, and Chiodo F (2004) Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53:10-14.
3. Caron M, Auclair M, Sterlingot H, Kornprobst M, and Capeau J (2003) Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 17:2437-2444.
4. Carr A (2000) HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30 (Suppl 2):S135-S142.
5. Cox JS, Chapman RE, and Walter P (1997) The unfolded protein response coordinates the production of endoplasmic reticulum protein and endoplasmic reticulum membrane. Mol Biol Cell 8:1805-1814.
6. Dino Rockel T and von Mikecz A (2002) Proteasome-dependent processing of nuclear proteins is correlated with their subnuclear localization. J Struct Biol 140:189-199.
7. Dowell P, Flexner C, Kwiterovich PO, and Lane MD (2000) Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 275:41325-41332.
8. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, and Niedermann G (2002) Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62:6901-6908.
9. Goetzman ES, Tian L, Nagy TR, Gower BA, Schoeb TR, Elgavish A, Acosta EP, Saag MS, and Wood PA (2003) HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses 19:1141-1150.
10. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, and Sension M (2003) Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 17:1339-1349.
11. Haerter G, Manfras B, Mueller M, Kern P, and Trein A (2004) Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 18:952-955.
12. Hertel J, Struthers H, Horj CB, and Hruz PW (2004) A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 279:55147-55152.
13. Hirano Y, Yoshida M, Shimizu M, and Sato R (2001) Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 276:36431-36437.
14. Hruz PW, Murata H, and Mueckler M(2001) Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol 280:E549-E553.
15. Hui DY (2003) Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 42:81-92.
16. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML, Hakim AM, Fienberg AA, and Thinakaran G (2004) Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24:9456-9469.
17. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, Wang X, Ron D, Cavener DR, and Wek RC (2004) Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 24:1365-1377.
18. Johnson N (2005) Atazanavir, with ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19:153-162.
19. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, and Arnold SM (2002) The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3:411-421.
20. Lenhard JM, Croom DK, Weiel JE, and Winegar DA (2000) HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 20:2625-2629.
21. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, and Sturley SL (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7:1327-1331.
22. Murata H, Hruz PW, and Mueckler M (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254.
23. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, and Giordano M (2003) Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17:2603-2614.
24. Nawaz Z and O'Malley BW (2004) Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol 18:493-499.
25. Nolan D and Mallal S (2004) The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 9:34-40.
26. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT, and Haas DW (2004) The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 18:2137-2144.
27. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, and Grunfeld C (2002) Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-F8.
28. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, and Hotamisligil GS (2004) Endoplasmic reticulum stress links obesity, insulin action and type 2 diabetes. Science (Wash DC) 306:457-461.
29. Pajonk F, Himmelsbach J, Riess K, Sommer A, and McBride WH (2002) The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62:5230-5235.
30. Pan Y, Chen H, Siu F, and Kilberg MS (2003) Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J Biol Chem 278:38402-38412.
31. Parker R, Wang S, Mulvey R, Fenderson W, Elosua C, Laing N, Yang W-P, and Flint O (2003) Proteasome and glucose transport inhibition: a unifying hypothesis for the mechanism of protease inhibitor-induced metabolic disturbances and for the superior lipid profile of atazanavir. Antivir Ther 8:S380.
32. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, and Brunzell JD (2000) Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57.
33. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, and Hui DY (2001) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276:37514-37519.
34. Rodgers KJ and Dean RT (2003) Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 35:716-727.
35. Sanne I, Piliero P, Squires K, Thiry A, and Schnittman S (2003) Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32:18-29.
36. Schmidtke G, Holzhutter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, and Groettrup M (1999) How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 274:35734-35740.
37. Shen Y, Meunier L, and Hendershot LM (2002) Identification and characterization of a novel endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro and is induced by ER stress. J Biol Chem 277:15947-15956.
38. Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H, and Kilberg MS (2002) ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J Biol Chem 277:24120-24127.
39. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, et al. (2004) Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36:1011-1019.
40. Travers KJ, Patil CK, Wodicka L, Lockhart DJ, Weissman JS, and Walter P (2000) Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell 101:249-258.
41. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, et al. (2001) Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Investig 107:1263-1273.
42. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, and Gerich JE (2003) Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52:918-925.
43. Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, et al. (2004) Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 36:684-692.
44. Zimmermann J, Erdmann D, Lalande I, Grossenbacher R, Noorani M, and Furst P (2000) Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 19:2913-2920.